ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ensysce Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.50−0.02 (-2.97%)
Close on Oct 19, 2026
- Market cap
- $6.56M
- P/E (TTM)
- –
- Dividend yield
- –
Ensysce Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| MPAR [Member] | $5.07M | $3.09M | $1.29M | $2.01M | $2.65M | – | 100.0% | +64.2% |
| TAAP/OUD [Member] | – | $2.12M | $937.28K | $516.50K | $884.62K | – | – | – |
By region
From the segment and revenue-disaggregation notes of Ensysce Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.